September 16, 2021

Yardley, PA - Red Nucleus (“RN”), a premier provider of learning, performance, and process solutions for the life sciences industry, announced the launch of a new business unit focused on clinical study design and operations in rare disease and specialty pharma. The new business will operate under the name Red Nucleus Clinical Research and is part of the new Scientific Services division.

The new business grows out of the acquisition earlier this year of iTakeControl Health ("ITC”). The ITC platform allows patients, clinicians, and sponsors to conduct clinical video assessments as well as real-time clinical remote visits and contains a full suite of ePRO data in compliance with FDA regulations. The iTakeControl platform will continue with the software-as-a-service product offering for Red Nucleus Clinical Research business.

Red Nucleus Clinical Research will continue to specialize in research advisory services, clinical operational support, and technology, with leading global biotech and pharmaceutical clients in gene therapy, a broad range of diseases and conditions, registries, and post-approval long-term follow-up studies.

With Red Nucleus Clinical Research, our team enhances both its product portfolio and its service offering across the life cycle of R&D, medical communications, and learning and development services. ITC’s technology application complements RN’s product suite, including a global labeling compliance tool (DirectusPRO), a learning and engagement platform (Unify), off-the-shelf training courses (LSTI), and a gaming platform (Rcade).

“We are dedicated to supporting the transfer of knowledge on the quest to make life better for patients around the world. RN Clinical supports this mission by delivering leading technology and services to the clinical trial market, with a focus on rare diseases. I am thrilled to further invest in the RN Clinical team as we continue to deliver leading edge services to our clients and patients,” said Red Nucleus CEO Ian Kelly.

Chris Jones, one of the lead partners in Red Nucleus Clinical Research, adds, “We have been providing clinical services as ITC since 2015. This new chapter allows us to continue to expand what we do globally under the Red Nucleus brand, and we look forward to our personalized services for our clinical sponsors looking for a true partner in their clinical development program.”